Jaroslaw Niebrzydowski

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

Jung‐Yoon Choe, Nenad Prodanović, Jaroslaw Niebrzydowski et al. · Annals of the Rheumatic Diseases · 2015 · 165 citations · Full text

Phase <scp>III</scp> Randomized Study of <scp>SB</scp>5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

Michael E. Weinblatt, Asta Baranauskaitė, Jaroslaw Niebrzydowski et al. · Arthritis & Rheumatology · 2017 · 130 citations · Full text

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

Josef S Smolen, Jung‐Yoon Choe, Nenad Prodanović et al. · Annals of the Rheumatic Diseases · 2017 · 121 citations · Full text

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results

Josef S Smolen, Jung‐Yoon Choe, Nenad Prodanović et al. · Lara D. Veeken · 2017 · 54 citations · Full text

FRI0162 Comparable Safety and Immunogenicity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study

Josef S Smolen, J.‐Y. Choe, Nenad Prodanović et al. · Annals of the Rheumatic Diseases · 2016 · 10 citations